Mechanistic target of rapamycin complex 1 and 2 (mTORC1/2)

Mechanistic target of rapamycin complex 1 and 2 (mTORC1 and mTORC2) are two distinct multi-protein complexes containing the serine/threonine protein kinase, mTOR, as their catalytic core. mTORC1 includes mTOR, Raptor, mLST8, PRAS40, and DEPTOR and is sensitive to inhibition by rapamycin; it integrates nutrient, energy, and growth factor signals to regulate protein synthesis, cell growth, and autophagy. mTORC2 contains mTOR, Rictor, mLST8, mSIN1, Protor, and DEPTOR and is generally rapamycin-insensitive; it functions as a master regulator of cell survival, metabolism, and cytoskeletal organization by phosphorylating kinases such as Akt, SGK1, and PKC. Dysregulated mTORC1/2 signaling is implicated in cancer, metabolic, and neurodegenerative diseases. mTORC1/2 are considered premier therapeutic targets in oncology and other diseases due to their central roles in cell and metabolic regulation[1][2][3][4][5][6][7][8].

Other names

mTORC1 (mammalian/mechanistic target of rapamycin complex 1)mTORC2 (mammalian/mechanistic target of rapamycin complex 2)rapamycin-sensitive complex (mTORC1)rapamycin-insensitive complex (mTORC2)mechanistic target of rapamycin complexes

Allosteric inhibition of kinase activity (e.g., by rapamycin for mTORC1) ATP-competitive inhibition (by selective or dual mTORC1/mTORC2 inhibitors) Suppression of downstream signaling pathways (e.g., S6K, 4E-BP1 for mTORC1; Akt, PKC for mTORC2)